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 After activation, CD4 + Th cells diff erentiate 
into distinct eff ector subsets that are character-
ized by their unique cytokine expression and 
immunoregulatory function ( 1, 2 ). A novel 
Th subset — termed Th IL-17 , Th17, or infl am-
matory Th — has been recently identifi ed as a 
distinct Th lineage that mediates tissue infl am-
mation ( 3 – 5 ). Th17 diff erentiation is initiated 
by TGF-  and IL-6 ( 4, 6, 7 ), and reinforced by 
IL-23 ( 8 ) and IL-21 ( 9 – 11 ), in which STAT3 
and two orphan nuclear receptors, ROR  and 
ROR  , mediate the lineage specifi cation ( 8, 
12 – 14 ). Despite rapid progress in understand-
ing the molecular programs that govern Th17 
diff erentiation, it is not clear how their prolif-
eration, and ultimately function, are regulated in 
the context of immune responses and diseases. 
 Th cell activation and diff erentiation re-
quires not only the recognition of the antigen –
 MHC class II complex by the cognate TCR but 
also co-stimulatory signals. Previous experi-
ments have indicated diff erential co-stimula-
tory regulation of Th1 and Th2 cell function 
( 15 ). Over the past decade, our knowledge 
of how diff erent ligand – receptor pairing inter-
actions contribute to T cell co-stimulation has 
been steadily expanded. Most of these pairs 
belong to either the B7-type molecules that 
bind CD28-like Ig superfamily receptors, or the 
TNF superfamily ligands that engage their re-
ceptor counterparts in the TNFR family ( 16 ). 
Although we have previously shown essen-
tial roles of CD28 and inducible co-stimulator 
in Th17 diff erentiation ( 17, 18 ), the func-
tional contribution of TNF and TNFR family 
members in regulating Th17 cell function is 
poorly understood. 
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 T helper type 17 (Th17) cells play an important pathogenic function in autoimmune dis-
eases; their regulation, however, is not well understood. We show that the expression of a 
tumor necrosis factor receptor family member, death receptor 3 (DR3; also known as 
TNFRSF25), is selectively elevated in Th17 cells, and that TL1A, its cognate ligand, can 
promote the proliferation of effector Th17 cells. To further investigate the role of the 
TL1A – DR3 pathway in Th17 regulation, we generated a TL1A-defi cient mouse and found 
that TL1A   /   dendritic cells exhibited a reduced capacity in supporting Th17 differentiation 
and proliferation. Consistent with these data, TL1A   /   animals displayed decreased clinical 
severity in experimental autoimmune encephalomyelitis (EAE). Finally, we demonstrated 
that during EAE disease progression, TL1A was required for the optimal differentiation as 
well as effector function of Th17 cells. These observations thus establish an important 
role of the TL1A – DR3 pathway in promoting Th17 cell function and Th17-mediated 
autoimmune disease. 
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interaction is important for the optimal function of Th17 cells 
and contributes to Th17-mediated  autoimmune disease. 
 RESULTS 
 Th17 cells highly express DR3 
 Although considerable progress has been made in identifying 
the various cytokines and transcriptional factors critical for 
Th17 diff erentiation, molecular pathways selectively regulat-
ing the expansion and function of this important Th subset 
remain unclear. To address this, we analyzed gene expression 
profi les by microarray analysis of Th1, Th2, and Th17 eff ec-
tor cells and discovered that expression of DR3 (TNFRSF25), 
which binds to TNF family member TL1A, was signifi cantly 
enhanced in Th17 cells when compared with the other two 
Th subsets (unpublished data). Because TNF family members 
regulate cell proliferation and survival, this result suggests the 
possibility that DR3 – TL1A interaction may be involved in 
the regulation of Th17 cells. To further confi rm this observa-
tion, CD4 + T cells from OT-II TCR transgenic mice were 
diff erentiated under Th1, Th2, or Th17 conditions, and 
mRNA was prepared on day 5 after restimulation and ana-
lyzed for DR3 expression by real-time PCR analysis. As 
shown in  Fig. 1 A , total DR3 expression was greatly increased 
in the Th17 subset compared with Th1 and Th2 cells, using 
a primer pair that allows detection of all DR3 isoforms. Fur-
thermore, DR3 expression was not detected during the fi rst 
2 d of diff erentiation but was up-regulated by day 5 ( Fig. 1 B ), 
suggesting that DR3 up-regulation occurs at a later stage of 
Th17 diff erentiation. 
 Previous studies have shown that TGF-  and IL-6 play 
essential roles in the diff erentiation of Th17 cells ( 4, 6, 7 ). To 
identify the cytokine pathways involved in DR3 up-regulation, 
naive OT-II T cells were activated under diff erent cytokine 
or Th17 conditions, mRNA was prepared from these cells on 
day 5 after activation, and total DR3 expression was analyzed 
by real-time PCR analysis. As shown in  Fig. 1 C , TGF-  alone 
induced DR3 expression, whereas IL-6 was not suffi  cient 
for DR3 induction. However, induction of DR3 is further 
enhanced in the presence of both TGF-  and IL-6 ( Fig. 1 C ). 
Additionally, the blocking of IFN-  and IL-4 in the pres-
ence of TGF-  and IL-6 (Th17 conditions) did not further 
enhance DR3 expression ( Fig. 1 C ), suggesting that TGF-  
and IL-6 alone are suffi  cient to induce DR3 expression. 
 Among the three known DR3 isoforms in the mouse, 
variant 1 is the full-length DR3 that is capable of both ligand 
binding and intracellular signaling. Variant 2 is a soluble DR3 
isoform that likely functions as a decoy receptor. Although 
variant 3 does contain both transmembrane and cytoplasmic 
domains, it lacks the fourth cysteine-rich domain in its extra-
cellular region, and its capacity for ligand binding has yet 
to be determined ( 30 ). Therefore, it is critical to determine 
which isoforms are induced upon Th17 diff erentiation. Us-
ing isoform-specifi c primers, we found that the full-length, 
functioning variant 1 was highly up-regulated in Th17 cells 
( Fig. 1, D and E ). 
 Within the TNF family, CD40L, OX-40L, LIGHT, 
CD27L (CD70), and 4-1BBL have well-established func-
tions in T cell activation and diff erentiation ( 16, 19 ). Recent 
evidence suggests that another TNF family member, TL1A 
(Tnfsf15), also plays a role in T cell regulation. TL1A was fi rst 
identifi ed as a protein expressed on human endothelial cells 
and up-regulated in response to TNF-  and IL-1  ( 20 ), al-
though an earlier study only identifi ed an irregularly spliced 
transcript. Subsequently, full-length TL1A was cloned, and 
expression of TL1A by human tissue macrophages, lamina 
propria T cells and plasma cells, and Fc  R-activated periph-
eral blood (PB) monocytes and monocyte-derived DCs was 
demonstrated ( 21 – 24 ). TL1A binds death receptor 3 (DR3; 
also called TNFRSF25), a death domain – containing TNFR 
family member that signals via NF-  B ( 25, 26 ). DR3 expres-
sion is signifi cantly increased upon T cell activation and was 
initially thought to be restricted to lymphocytes ( 27 ). How-
ever, recent data have expanded the number of cell types that 
express DR3 to also include NK cells, macrophages, and en-
dothelial cells ( 22, 28, 29 ). Although DR3-defi cient mice 
exhibit a partial impairment in the negative selection of thy-
mocytes ( 30 ), the impact of DR3 defi ciency on immune 
function has not been further explored. TL1A also binds to 
DcR3 ( 20 ), a decoy receptor for TL1A, LIGHT, and FasL 
that is present in humans but not mice ( 31 ), suggesting addi-
tional complexity in the role of this pathway in humans. 
 Several lines of evidence point to a role for TL1A in 
modulating T cell activation. Under conditions of subopti-
mal anti-CD3/CD28 stimulation, TL1A increases IL-2 –
 driven proliferation and IFN-  and GM-CSF production by 
human PB T cells, and in vivo administration of recombi-
nant TL1A enhances mouse graft-versus-host reactions ( 20 ). 
Thus, despite the presence of a death domain in DR3, bind-
ing of TL1A to DR3 on T cells provides a co-stimulatory 
signal ( 20 ). TL1A also synergizes with IL-12 and IL-18 in 
stimulating TCR-independent secretion of IFN-  by human 
PB CD4 + memory T cells ( 29, 32 ). The ability of TL1A to 
co-stimulate IFN-  secretion and the association of TL1A 
expression with areas of active infl ammation in Crohn ’ s 
disease have led to the hypothesis that TL1A acts as a Th1-
polarizing cytokine ( 21, 29, 32 ). However, it was more recently 
shown that TL1A acted preferentially to enhance TCR-
stimulated proliferation of memory CD4 + T cells ( 33 ), which 
was associated with an increased capacity of memory T cells 
to express IFN-  . 
 In the current study, we found that full-length DR3 ex-
pression is selectively elevated in Th17 cells and mediates their 
development and proliferation. Defi ciency in TL1A in DCs 
substantially reduced their ability in supporting Th17 diff eren-
tiation and proliferation. Consistently, TL1A KO animals ex-
hibited decreased Th17 generation in vivo and reduced disease 
severity upon induction of experimental autoimmune enceph-
alomyelitis (EAE). Additionally, the absence of TL1A in recip-
ient mice also resulted in reduced severity of EAE disease 
induced by adoptive transfer of autoreactive Th17 cells. 
Collectively, these observations demonstrate that DR3 – TL1A 
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 Because TL1A has been shown to enhance proliferation 
and IFN-  secretion in CD4 + memory T cells ( 21, 33 ), we 
examined the eff ect of TL1A on in vitro – diff erentiated Th1 
and Th17 cells. Th1 and Th17 cells were incubated with a ti-
trating dose of anti-CD3 and in the presence or absence of 
TL1A, and proliferation was measured by [ 3 H]thymidine 
incorporation. Culture supernatants were analyzed for IFN-  
or IL-17 production by ELISA. As shown in  Fig. 3 A , TL1A 
did not aff ect the proliferation or IFN-  production by Th1 
eff ector cells. However, addition of TL1A greatly enhanced 
the proliferation of Th17 cells, especially at lower concentra-
tions of anti-CD3 stimulation ( Fig. 3 B ). More signifi cantly, 
in the absence of TCR stimulation, TL1A treatment did not 
enhance the proliferation of Th1 cells, whereas the prolifera-
tion of Th17 cells was greatly increased ( Fig. 3, A and B ). 
Despite increased proliferation upon TL1A stimulation, IL-
17 production was not increased under these conditions in 
the culture supernatants ( Fig. 3, A and B , bottom) or by in-
tracellular staining (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20071364/DC1), suggesting that the 
primary function of the TL1A – DR3 pathway in Th17 cells 
may be to enhance cellular proliferation. 
 Because TL1A alone induced Th17 cell proliferation, we 
further analyzed the proliferation of Th17 cells at diff erent 
concentrations of TL1A. As shown in  Fig. 3 C , prolifera-
tion of Th17 cells was greatly enhanced with increased con-
centration of Fc-TL1A, whereas the proliferation of Th1 
cells remained unchanged even at the highest concentration 
(1  μ g/ml) of TL1A. Collectively, these results revealed a pre-
viously unknown and specifi c regulation of Th17 cells by the 
TL1A – DR3 interaction. 
 Because TGF-  also induces Foxp3 expression in acti-
vated T cells, we examined whether T reg cells expressed 
DR3. Interestingly, both naturally occurring T reg (n – T reg) 
and TGF-  – induced T reg (i – T reg) cells up-regulated DR3 
expression ( Fig. 1, D and E ). However, the full-length vari-
ant 1 represents a much higher proportion of the total DR3 
isoforms expressed in Th17 cells as compared with n – T reg 
or i – T reg cells, supporting the preferential involvement of 
TL1A – DR3 interaction in regulating Th17 cell function. 
 TL1A stimulation regulates Th17 development 
and proliferation 
 To establish the potential biological relevance of DR3 ex-
pression on Th17 cells, we fi rst tested the eff ect of recombi-
nant Fc-TL1A protein on Th17 diff erentiation, proliferation, 
and cytokine expression. Naive CD4 + T cells were activated 
with plate-bound anti-CD3/CD28 in the presence or ab-
sence of Fc-TL1A and in the presence of TGF  + IL-6 or 
Th17 diff erentiation conditions. In comparison to cells treated 
with a control Fc-containing protein, Fc-TL1A enhanced 
IL-2 secretion ( Fig. 2 A ). It has been recently shown that IL-2 
signaling inhibits Th17 diff erentiation in a STAT5-dependent 
manner ( 34 ). Consistently, percentages of IL-17 – producing 
cells were decreased by 40% in T cells diff erentiated in the 
presence of Fc-TL1A ( Fig. 2 B ). However, upon treatment 
with an anti – IL-2 antibody, Fc-TL1A enhanced the diff eren-
tiation of Th17 cells by 35% under TGF  + IL-6 conditions 
and 20% under Th17 conditions ( Fig. 2 B ). These results sug-
gest that in the absence of IL-2 signaling, TL1A – DR3 inter-
action could function to enhance the diff erentiation of Th17 
cells from naive T cells. 
 Figure 1.  DR3 expression is greatly enhanced in Th17 cells. Naive OT-II cells were differentiated and DR3 expression was analyzed by real-time PCR 
analysis. DR3 expression was determined relative to naive CD4 + T cell expression levels and normalized to GAPDH levels in all samples. (A) Comparison of 
DR3 expression on CD4 + cells differentiated under Th1, Th2, and Th17 conditions. (B) Time-course analysis of DR3 expression in CD4 + T cells differentiat-
ing under Th17 conditions. (C) Analysis of DR3 expression in cells differentiated under different combinations of cytokines. Primers used in A – C detect all 
DR3 isoforms. (D) Analysis of the full-length transmembrane-containing DR3 isoform (variant 1) in Th17 and T reg cells. (E) The ratio of total transmem-
brane DR3 (variants 1 and 3 combined) and full-length transmembrane DR3 (variant 1) was measured in Th17 and T reg cells. Error bars represent SD. 
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 TL1A-defi cient DCs exhibit reduced potency to induce Th17 
differentiation and proliferation 
 Because Fc-TL1A enhanced the diff erentiation and prolifera-
tion of Th17 cells, we tested the impact of TL1A defi ciency 
in APCs on the diff erentiation of naive T cells into Th17 
cells. LPS-stimulated bone marrow – derived DCs (BMDCs) 
from WT and TL1A KO mice were pulsed with OT-II pep-
tide and used for activating naive OT-II CD4 T cells under 
Th1 and Th17 diff erentiation conditions. The development 
of eff ector cells was monitored by intracellular cytokine stain-
ing for IL-17 and IFN-  on day 6 after stimulation. As shown 
in  Fig. 5 , diff erentiation of Th1 cells was not aff ected because 
of TL1A defi ciency; however, when OT-II CD4 T cells 
were diff erentiated with KO BMDCs, we observed a mod-
est, yet reproducible, decrease in the percentage of Th17 cells 
generated ( Fig. 5 ). These results are in agreement with our 
earlier in vitro results on the diff erentiation of naive CD4 + T 
cells with recombinant Fc-TL1A ( Fig. 2 ), which indicate that 
TL1A expressed on APCs may promote the diff erentiation of 
Th17 cells. The eff ect on Th17 cells appears quite specifi c, as 
exogenous TL1A did not have any eff ect on T reg cell diff er-
entiation induced by TGF-  (Fig. S3 A, available at http://
www.jem.org/cgi/content/full/jem.20071364/DC1), even 
 Because DR3 expression was observed in both n – T reg 
and i – T reg cells ( Fig. 1, D and E ), we also tested whether 
Fc-TL1A could infl uence their proliferation. As shown in 
 Fig. 3 D , Fc-TL1A specifi cally induced the proliferation of 
Th17 but not n – T reg, i – T reg, or Th1 cells, suggesting that 
the relative expression levels of diff erent DR3 isoforms may 
determine the TL1A responsiveness of a given cell type. 
 Generation of TL1A-defi cient mice 
 To further understand the function of TL1A – DR3 interaction 
in regulating Th17 cells in vivo, a TL1A KO mouse was gen-
erated by replacing exon 4 of the TL1A ( Tnfsf15 ) locus with a 
neomycin cassette ( Fig. 4 A ). Exon 4 encodes amino acids 
103 – 252 of TL1A, encompassing the TNF homology domain 
that is essential for TL1A function. Lack of TL1A expression 
was confi rmed by RT-PCR of kidney tissues ( Fig. 4 B ), which 
contain high levels of TL1A mRNA ( 20, 35 ). TL1A KO mice 
appeared phenotypically normal, and similar immune cell num-
bers and proportions were observed in the lymph nodes, spleen, 
thymus, and bone marrow ( Fig. 4 C ; and Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20071364/DC1). 
These results suggest that TL1A is likely not critical for the 
development of lymphocytes and peripheral lymphocytes. 
 Figure 2.  TL1A enhances the differentiation. (A) The addition of TL1A during naive T cell activation increases IL-2 production. Naive CD4 + T cells 
were stimulated with plate-bound anti-CD3/CD28 antibody under the indicated conditions. Culture supernatants were analyzed for IL-2 24 h later by 
ELISA. Data represent the mean of triplicate cultures, and error bars represent SD. Results are representative of three independent experiments with simi-
lar results. (B) TL1A regulates Th17 differentiation. Naive CD4 + T cells were stimulated by plate-bound anti-CD3/CD28, in the presence of control Ig or 
1  μ g/ml Fc-TL1A, and under Th17-differentiating conditions in the absence or presence of anti – IL-2 antibodies. The percentages of IL-17 – and IFN-  – 
producing cells were measured by intracellular cytokine staining. Data are a representative of three independent experiments with similar results. 
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trast, in the absence of TCR signaling, WT BMDCs greatly 
enhanced the proliferation of Th17 cells, and this enhance-
ment eff ect was signifi cantly diminished when TL1A-defi cient 
BMDCs were used ( Fig. 6 A ). Importantly, the addition of 
exogenous Fc-TL1A to the latter culture condition restored 
the enhancement eff ect ( Fig. 6 B ), clearly demonstrating that 
the ability of WT BMDCs to promote antigen-independent 
proliferation of Th17 cells requires TL1A expression. Even in 
the presence of OVA peptide, the proliferation of Th1 cells 
stimulated by WT and TL1A-defi cient BMDCs was similar, 
whereas the proliferation of Th17 cells was once again re-
duced using TL1A-defi cient BMDCs ( Fig. 6 C ). Interest-
ingly, the reduced proliferation of Th17 cells in the absence 
though these cells also up-regulate DR3 expression. Con-
versely, although OT-II CD4 T cells activated by TL1A KO 
BMDCs exhibited reduced Th17 diff erentiation based on in-
tracellular IL-17A staining, Foxp3 expression was not recip-
rocally increased (Fig. S3 B). 
 Because Fc-TL1A promoted Th17 cell proliferation, we 
also assessed the impact of TL1A defi ciency in APCs on the 
expansion of diff erentiated Th17 cells. In vitro – diff erentiated 
Th1 and Th17 cells were either left alone or incubated with 
WT or TL1A-defi cient BMDCs, and their proliferation was 
measured by [ 3 H]thymidine incorporation at 24 h. As shown 
in  Fig. 6 A , the proliferation of Th1 cells was not aff ected by 
the presence of either WT or TL1A KO BMDCs. In con-
 Figure 3.  TL1A enhances the proliferation of Th17 effector cells. (A and B) In vitro – differentiated Th1 and Th17 cells were restimulated on day 5 
after activation with the indicated doses of anti-CD3 with or without 1  μ g/ml of exogenous Fc-TL1A or control human Ig. Proliferation of Th1 cells (A) 
and Th17 cells (B) was determined by [ 3 H]thymidine incorporation after 24 h of stimulation. In a parallel experiment, culture supernatant was analyzed for 
IFN-  (A) and IL-17 (B) expression by ELISA. Data are representative of three independent experiments. (C) In vitro – differentiated Th1 and Th17 cells were 
restimulated with the indicated doses of exogenous Fc-TL1A. (left) The proliferation of Th1 and Th17 cells was determined by [ 3 H]thymidine incorporation 
after 24 h of stimulation. (right) The proliferation of Th1 and Th17 cells in the absence or presence of 1  μ g/ml Fc-TL1A was represented. Results are repre-
sentative of three independent experiments. (D) TL1A specifi cally enhances Th17 cell proliferation. In vitro – differentiated Th1 and Th17 cells, and n – T reg 
and i – T reg cells were stimulated with control Ig or 1  μ g/ml Fc-TL1A for 24 h. Proliferation was determined by [ 3 H]thymidine incorporation during the last 
8 h of stimulation. Proliferation in the presence of positive controls was as follows: anti-CD3 for Th1 and Th17 cells (14,000 and 30,000 CPM, respec-
tively), and IL-2 for n – T reg and i – T reg cells (98,000 and 25,000 CPM, respectively). Data are representative of two independent experiments with similar 
results. Error bars represent SD. 
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tion of Th17 cells only under conditions of suboptimal TCR 
stimulation ( Fig. 3 B ). 
 TL1A defi ciency results in decreased severity of EAE disease 
 To determine the biological signifi cance of the TL1A – DR3 
pathway in vivo , we used a Th17-mediated autoimmune 
disease model, myelin oligodendrocyte glycoprotein (MOG)-
induced EAE ( 18, 36 ). In four independent experiments, 
TL1A KO and WT animals exhibited similar timing of dis-
ease onset, but TL1A KO mice consistently showed a signif-
icantly reduced disease severity, as manifested by both a 
lower maximal disease score and lower cumulative scores 
throughout the course of the disease ( Fig. 7 A and  Table I ). 
Although no statistical signifi cance was achieved, a consis-
tent trend toward lower disease incidence was observed in 
TL1A KO mice (unpublished data). 
 Histological examination of the spinal cords was per-
formed to determine whether the diff erence in clinical symp-
toms observed between TL1A KO and WT mice correlated 
with the degree of infl ammatory infi ltration and demyelin-
ation in the central nervous system (CNS). TL1A KO mice 
exhibited fewer mononuclear infi ltrates and demyelination 
foci than WT control animals at day 27 after immunization 
( Fig. 7, B and C ). These results indicate that the reduced 
clinical scores observed in the KO animals were likely caused 
by decreased infl ammation and tissue damage in the CNS. 
Because our in vitro studies suggest that the TL1A – DR3 
of TL1A was observed only when lower concentrations of 
OVA peptide were used ( Fig. 6 C ). These data are consistent 
with our earlier results that Fc-TL1A enhanced the prolifera-
 Figure 4.  TL1A targeting strategy and lymphocyte characterization from TL1A KO mice. (A) Restriction map of the mouse  Tnfsf15 locus and the 
thymidine kinase (TK) – and neomycin (neo)-containing targeting construct derived from it. Restriction enzyme sites indicated are as follows: Ba, BamHI; 
Bg, BglII; E, EcoRI; and X, XbaI. Exons are represented as black boxes, and arrows indicate the direction of transcription. (B) RT-PCR analysis of TL1A mRNA 
in TL1A KO and WT kidneys. (C) Surface phenotype of naive WT (white bars) and TL1A KO (gray bars) lymph node cells. (left) Percentages of total lympho-
cytes positive for the indicated markers are plotted. (right) Percentages of CD4 + or CD8 + T cells positive for the indicated marker combinations are plotted. 
Data represent means of eight animals per group, and error bars are SEM. 
 Figure 5.  Decreased differentiation of Th17 cells in response to 
stimulation by TL1A KO DCs. Naive OT-II CD4 + T cells were stimulated 
with either WT or TL1A KO BMDCs under polarized Th1- and Th17-differ-
entiating conditions. Cells were harvested on day 6 and restimulated 
with PMA plus ionomycin, followed by intracellular cytokine staining for 
IFN-  and IL-17. Dot plots represent the IFN-  and IL-17 expression 
among CD4 + cells (percentages are shown). Data are representative of 
three independent experiments. 
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clinical symptoms, and their levels peak at days 5 – 7 after dis-
ease onset (unpublished data) ( 37, 38 ). We found that the per-
centage of CD45 + CD4 + cells in the CNS of TL1A KO mice 
was consistently reduced as compared with WT animals over 
the course of the study ( Fig. 7, E and F ). Absolute numbers of 
CD45 + CD4 + cells were also examined and showed a similar 
trend (unpublished data). These observations show that the 
eff ect of TL1A defi ciency in reducing CD4 T cell levels in the 
CNS is evident early in and maintained throughout the dis-
ease course. In addition, there were dramatic reductions in the 
total numbers of recovered CD4 + T cells expressing proin-
fl ammatory cytokines such as IL-17, IFN-  , IL-6, and TNF-
  in day 17 CNS cell isolates ( Fig. 7 G ). 
 Function of TL1A in the generation, expansion, and effector 
function of autoreactive T cells 
 By signaling through its receptor DR3, TL1A could poten-
tially contribute to the pathogenesis of autoimmune diseases 
at multiple levels. We fi rst tested whether TL1A defi ciency 
aff ects T cell priming in EAE. WT and TL1A KO mice 
were immunized with MOG peptide in CFA, and lymph 
node and spleen cells were analyzed for IL-17 and IFN-  
expression on day 10. As shown in  Fig. 8 , the percentages 
of IL-17 – and IFN-  – expressing populations were signifi -
cantly decreased in TL1A KO mice. More impressively, a 
population of CD4 + T cells expressing both IL-17 and IFN-  
was observed in WT mice, and was most consistently and 
pathway may be involved in the generation and/or function 
of pathogenic MOG-specifi c T cells during the course of 
EAE, the levels of T cell infi ltration were further quantifi ed 
by image analysis of anti-CD3 staining. As shown in  Fig. 7 D , 
TL1A KO animals had fewer CD3 + cells per spinal cord cross 
section than WT counterparts. 
 Several distinct factors could potentially infl uence the 
degree of CNS T cell infi ltration in the context of EAE. 
To rule out the possibility that the lesser T cell infi ltration 
seen in the spinal cords of TL1A KO animals was caused 
by a reduced ability of their T cells to survive in the CNS, 
Tdt-mediated dUTP-biotin nick-end labeling and anti-ac-
tivated caspase-3 staining were performed to assess the ex-
tent of apoptosis in TL1A KO and WT CNS. The level of 
apoptosis in the WT spinal cord was low on days 21 or 27 
after immunization. Furthermore, no increase in apoptotic 
cells was observed in the KO spinal cords (unpublished 
data), suggesting that T cell apoptosis is unlikely to be a 
contributing factor underlying the reduced infi ltrating T 
cell numbers observed in the CNS of TL1A-defi cient ani-
mals with EAE. 
 To determine whether the reduction in CNS T cell fre-
quency seen on day 27 was caused by diff erent temporal ki-
netics between WT and KO animals, levels of CD4 + T cells 
in the CNS (spinal cord and cerebellum) were assessed at mul-
tiple time points by fl ow cytometry. CD4 + T cells start accu-
mulating in the CNS of WT mice 1 or 2 d before the onset of 
 Figure 6.  Reduced proliferation of Th17 cells upon restimulation by TL1A KO BMDCs. (A) In vitro – differentiated Th1 and Th17 cells were left 
unstimulated or restimulated on day 5 with WT or TL1A KO BMDCs for 24 h. Proliferation was measured by [ 3 H]thymidine incorporation during the last 8 h 
of stimulation. (B) In vitro – differentiated Th17 cells were stimulated with WT or TL1A KO BMDCs with and without Fc-TL1A for 24 h. Proliferation was 
measured by [ 3 H]thymidine incorporation during the last 8 h of stimulation. (C) In vitro – differentiated Th1 and Th17 cells were stimulated with WT or TL1A 
KO BMDCs pulsed with a titrating dose of OT-II peptide. The proliferation of Th1 and Th17 cells was determined at 24 h of stimulation by [ 3 H]thymidine 
incorporation. The horizontal dashed line represents the baseline proliferation of Th1 or Th17 cells alone. Data are representative of three independent 
experiments. Error bars represent SD. 
1056 TH17 CELL FUNCTION REGULATED BY TL1A | Pappu et al.
 Figure 7.  TL1A defi ciency protects mice from EAE. (A) EAE clinical course in TL1A KO animals. EAE disease course in TL1A KO and WT mice. 
Mice were immunized with MOG35-55 and pertussis toxin, as described in Materials and methods. Values represent the mean clinical score for each 
group. The disease course is representative of four independent experiments ( n = 7 – 10 animals per group). (B) Histological analysis. Spinal cord 
analysis at day 27 after immunization for TL1A KO, WT, and unimmunized WT (WT-untr) animals. Representative images are shown. Spinal cord cross 
sections were paraffi n embedded and stained with the indicated histochemical stains or the anti-CD3 antibody. Bar, 500  μ m. (C) Higher magnifi ca-
tion of the Luxol fast blue staining is shown. Bar, 200  μ m. (D) Quantifi cation of the number of CD3-positive cells per cross section in TL1A KO and 
WT animals on day 27 after immunization. Images were analyzed as described in Materials and methods. Results are shown for seven individual 
animals in each group and one unimmunized WT animal (untr). Symbols represent the number of CD3-positive cells per cross section; horizontal 
bars indicate means. (E and F) Kinetic analysis of CNS-infi ltrating T cells. CNS-infi ltrating leukocytes were isolated as described in Materials and 
methods. (E) Representative FACS plots of CD45 and CD4 staining (gated on CD45 + cells) are shown for the WT CNS untreated (left) and at day 17 
after immunization (right), with equal numbers of events plotted (percentages are shown). (F) Percentage of CD45 + CD4 + cells in the CNS of WT 
(white bars) and TL1A KO (gray bars) mice at the indicated days after immunization. Cells are gated as in  Fig. 7 E . Five to seven animals per group are 
shown; the black bar represents untreated WT mice. The reduction seen in the KO mice is statistically signifi cant for TL1A KO over the course of the 
experiment (P = 0.021, as determined by two-way analysis of variance). Error bars represent SD. (G) A reduced number of cytokine-expressing CD4 + T 
cells in TL1AKO CNS after MOG-EAE induction. CNS cell isolates of WT and TL1A KO mice (pools from six animals for each group) were analyzed on 
day 17 after disease induction. The absolute numbers of cytokine-positive CD4 + cells were determined by intracellular cytokine staining. Results are 
representative of two independent experiments. 
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 To defi nitively demonstrate that Th17 cells indeed re-
quire TL1A signaling to completely exert their disease-
driving capacities in vivo, we again took advantage of the 
discussed adoptive transfer model of EAE, except in this 
case the pathogenic Th17 cells were diff erentiated and ex-
panded in vitro under optimal IL-23 concentrations. The 
majority (  66 – 86%) of the resulting MOG-specifi c CD4 + 
T cells appeared to be IL-17 producing, based on intracel-
lular cytokine staining, and expressed DR3, including the 
full-length variant 1 isoform, as confi rmed by real-time 
PCR analysis (Fig. S6, available at http://www.jem.org/
cgi/content/full/jem.20071364/DC1). The in vivo role of 
TL1A in regulating the pathogenic functions of these largely 
diff erentiated Th17 cells was then assessed by examining 
EAE disease severities observed after adoptive transfer into 
either WT or TL1A KO mice.  Fig. 9 clearly shows that in 
comparison to WT recipients, the severity of EAE disease 
was signifi cantly reduced in TL1A KO mice, indicating 
that continuous TL1A signaling is in fact required in vivo 
for these transferred pathogenic T cells to achieve their 
maximal disease-driving potential. Consistently, the num-
bers of IL-17, IFN-  , and double-producing cells were all 
greatly reduced in the CNS infi ltrates of TL1A KO mice 
( Fig. 9 B ). These fi ndings thus confi rm the in vivo contri-
bution of the TL1A – DR3 pathway in regulating Th17 cell 
function and in promoting Th17-mediated autoimmune 
disease pathologies. 
 DISCUSSION 
 The recent identifi cation and characterization of Th17 lin-
eage cells have signifi cantly advanced our understanding of 
the pathogenic mechanisms underlying several infl ammatory 
dramatically reduced in the KO animals. Similar results were 
obtained with MOG restimulation (Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20071364/DC1). 
The frequency of Foxp3 + CD4 + cells was also measured 
after MOG restimulation of lymph node and spleen cells, 
with no signifi cant diff erence found between WT and TL1A 
KO mice (1.74 vs. 1.92% FoxP3 + CD4 + cells, respectively; 
unpublished data). These results are consistent with our in 
vitro diff erentiation results ( Fig. 2 A and  Fig. 5 ) and suggest 
that TL1A defi ciency impairs the priming of MOG-specifi c 
CD4 + T cells, which may contribute to decreased EAE se-
verity in TL1A KO mice. 
 Because TL1A promoted the proliferation and diff erenti-
ation of Th17 cells in vitro, we sought to test whether TL1A 
can also contribute to disease progression by expanding auto-
reactive T cells and/or potentiating their pathogenic eff ects 
in the context of EAE using an adoptive transfer model. 
Splenocytes and draining lymph node cells from MOG-
immunized mice were expanded in vitro with MOG pep-
tide and 5 ng/ml of suboptimal IL-23 in the presence of 
control Ig or Fc-TL1A. On day 10 after expansion, puri-
fi ed CD4 + T cells were counted, and 10 million cells were 
adoptively transferred into recipient mice to induce EAE. 
Our results showed that not only were more cells recov-
ered with Fc-TL1A treatment, but more importantly, when 
transferred with the same number of CD4 + T cells, mice re-
ceiving Fc-TL1A – expanded cells developed EAE disease 
with 100% disease incidence and a peak clinical score of 2 
(Fig. S5 A, available at http://www.jem.org/cgi/content/
full/jem.20071364/DC1), whereas mice receiving control 
Ig – expanded cells did not show any disease symptoms. Fur-
thermore, when CD4 + T cells from MOG-immunized mice 
were expanded without IL-23, only a portion of the recipi-
ents of CD4 + T cells cultured in the presence of MOG pep-
tide and Fc-TL1A showed minimal signs of EAE disease 
development, with a mean clinical score of 1.33 in aff ected mice 
with 60% disease incidence, whereas recipients of CD4 + T 
cells cultured with MOG peptide and control Ig did not 
show any disease symptoms (Fig. S5 B). Therefore, these re-
sults indicate that in addition to participating in the effi  cient 
priming of autoreactive T cells, TL1A may further contrib-
ute to T cell – mediated autoimmunity through promoting 
the proliferation of Th17 cells, as well as maximizing their 
pathogenic potential. 
 Table I.  Statistical parameters for MOG-EAE 
WT KO
Maximal score 3.7 2.6 (P = 0.014) a 
Cumulative score 56.9 37.6 (P = 0.002)
Day of onset b 12 14.2
Incidence 9/9 (100%) 7/9 (78%)
Values are for the experiment in  Fig. 7 .
 a p-values are shown for TL1A KO versus WT groups based on the Mann-Whitney 
nonparametric test.
 b Day of onset was calculated for diseased animals only.
 Figure 8.  Reduced T cell Priming in MOG-immunized TL1A KO 
mice. WT and TL1A KO mice were primed with MOG-CFA, and draining 
lymph nodes and spleen were harvested on day 10. Single-cell suspen-
sions were stimulated with PMA plus ionomycin with Golgi Plug for 4 h, 
stained, and analyzed by fl ow cytometry. Percentages of IL-17 – and/or 
IFN-  – secreting cells among CD4 + cells are shown. Values shown are 
means  ± SEM ( n = 12 mice per group). Results are compiled from two 
experiments with similar results. Differences between WT and KO mice are 
signifi cant for each of the cytokine-expressing populations (IL-17 + , P = 
0.004; IFN-  + , P = 0.002; IL-17 + IFN-     , P = 0.019; IFN-  + IL-17    , P = 
0.011; and IL-17 + IFN-  + , P = 0.005, as determined by the Student ’ s  t test). 
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not investigated. Our results show that DR3 expression is 
 enhanced in Th17 cells compared with Th1 and Th2 cells. 
Although diff erentiation of naive CD4 + T cells into Th17 cells 
is promoted by the combinatorial action of TGF-  and IL-6 
( 4, 7 ), our results reveal a novel role for TL1A in regulating 
Th17 diff erentiation. Although TL1A protein inhibited Th17 
diff erentiation in vitro via increased IL-2 production, it pro-
moted Th17 diff erentiation in the absence of IL-2 signaling. 
Consistently, lack of TL1A on DCs resulted in decreased 
Th17 diff erentiation by OT-II T cells. In these experiments, 
TL1A may act during the early stages of Th17 commitment 
and/or promote the expansion of Th17 lineage cells during 
diff erentiation. It has been proposed that Th17 survival and 
expansion are dependent on IL-23 ( 7, 39 ), and that IL-23 
maintains their pathogenic potential ( 40 ); the precise function 
of IL-23 remains to be determined. Our observations suggest 
that TL1A expands Th17 cells and enhances the pathogenic 
potential of these cells when cultured with IL-23 at subopti-
mal levels. TL1A may thus synergize with IL-23 signaling in 
promoting the optimal eff ector functions of pathogenic T 
cells; the lack of this regulation may thus have contributed to 
reduced severity of EAE disease in the TL1A KO mice. 
 TL1A plays a specifi c role in expanding Th17 eff ector cells 
even in the absence of TCR stimulation, whereas IL-17 secre-
tion was not increased upon TL1A stimulation, suggesting 
that TL1A primarily supports the proliferation of Th17 cells. 
It is possible that IL-17 secretion upon TL1A stimulation may 
require additional signaling pathways, e.g., from TCR or IL-
23R. In contrast, TL1A did not aff ect expansion or IFN-  se-
cretion by in vitro – diff erentiated eff ector Th1 cells. Moreover, 
our data indicate that Th17 but not Th1 cell proliferation is 
supported by mature DCs independent of TCR stimulation. 
The signifi cance of this fi nding is unclear at this stage, but this 
regulation may result in the expansion of Th17 cell numbers 
in the infl ammatory tissues, which is important for early host 
defense against certain infection or infl ammatory autoimmune 
diseases such as EAE. The homeostatic proliferation of Th17 
cells in response to mature DCs appears to be dependent on 
TL1A – DR3 interaction, as expansion of Th17 eff ector cells is 
selectively impaired in the presence of TL1A KO BMDCs. 
Our results suggesting the specifi c role of TL1A in Th17 ef-
fector cell expansion diff er from previous reports that TL1A 
promotes expansion and IFN-  secretion by Th1 cells. How-
ever, previous studies used mouse and human memory T cells 
that were generated in vivo. In addition, they did not examine 
the eff ect of TL1A on IL-17 or Th17 cells, nor did they dem-
onstrate a role for endogenous TL1A in regulating IFN-  
production ( 33 ). At this point, it is possible that TL1A regula-
tion of eff ector and memory cells diff ers. Additionally, TL1A-
mediated eff ects on Th1 cells may require the synergistic 
action of additional signaling pathways such as IL-12 or IL-18 
cytokines, whereas TL1A alone is suffi  cient to induce Th17 
proliferation ( 33 ). Further experiments are needed to explore 
the diff erences in the action of TL1A on Th17 and Th1 eff ec-
tor and memory CD4 + T cells, which may shed additional 
light on the novel function of TL1A. 
and autoimmune diseases ( 3 – 5, 39 ). Compared with the con-
siderable progress on the various pathways important for the 
diff erentiation of Th17 cells from naive CD4 + T cells, little is 
known regarding the regulatory mechanisms governing the 
proliferation and function of eff ector Th17 cells. In this study, 
we have identifi ed the TNF family ligand – receptor pairing of 
TL1A – DR3 as a novel regulator of Th17 cells. 
 TL1A, a member of the TNF superfamily, exerts its eff ects 
by binding and signaling through DR3 ( 19 ). Previous studies 
have shown that recombinant TL1A enhances the IL-2 re-
sponsiveness of TCR-activated human CD4 + T cells and pro-
motes IFN-  secretion, and synergizes with IL-12 and IL-18 
in stimulating TCR-independent secretion of IFN-  by hu-
man PB CD4 + memory T cells ( 20, 32 ). Additionally, mouse 
memory CD4 + T cells were reported to proliferate in response 
to TL1A stimulation, whereas naive CD4 + T cells were unre-
sponsive ( 33 ). However, the eff ect of TL1A on Th17 cells was 
 Figure 9.  EAE induced by adoptive transfer of MOG-specifi c Th17 
cells is dependent on TL1A. CD4 + T cells from MOG-primed WT animals 
were expanded in vitro in the presence of MOG peptide and IL-23 and 
adoptively transferred into WT and TL1A KO mice. (A) EAE clinical course 
in WT and TL1A KO mice ( n = 11 – 12 mice per group). Results shown are 
compiled from two independent experiments. Disease severity was signifi -
cantly reduced in KO mice (WT vs. KO mean cumulative score, P = 0.04; 
and mean maximal score, P = 0.05, as determined by the Mann Whitney 
nonparametric test), with no difference in disease incidence (WT, 9 out of 
11 mice; KO, 10 out of 12 mice). Disease onset tended to be delayed (P = 
0.06, as determined by the Student ’ s two-tailed  t test). (B) Mononuclear 
infi ltrating cells from the CNS of WT and TL1A KO mice (pools of fi ve ani-
mals) at day 24 after adoptive transfer were restimulated with PMA plus 
ionomycin and analyzed by intracellular cytokine staining. The absolute 
number of IL-17 – and/or IFN-  – expressing CD4 + T cells are shown. 
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Because TL1A and DR3 have been implicated in other in-
fl ammatory diseases ( 41 ), targeting this pathway may be ben-
efi cial in patients with Th17-mediated diseases. 
 MATERIALS AND METHODS 
 Mice.  TL1A KO mice were generated on the 129/Sv background by a tar-
geted deletion of exon 4 of the TL1A locus on chromosome 4C1. TL1A 
defi ciency was confi rmed by RT-PCR on kidney tissues previously shown 
to express high levels of TL1A mRNA ( 20, 35 ). Mice were maintained at 
Biogen Idec or the M.D. Anderson Cancer Center animal facility in compli-
ance with Institutional Animal Care and Use Committee (IACUC) guide-
lines. TL1A-defi cient mice were backcrossed onto the C57BL/6 background 
for 5 – 10 generation for these experiments. Mice were genotyped for TL1A 
defi ciency using a PCR-based assay on genomic DNA from tail biopsy sam-
ples. EAE experiments were conducted with mice backcrossed to the 
C57BL/6 strain for 6 or 10 generations with similar results. All animal ex-
periments were performed based on the protocol approved by the IACUCs 
at M.D. Anderson Cancer Center or Biogen Idec. 
 Gene expression analysis.  Diff erentiating CD4 + T cells were harvested at 
the times indicated in the fi gures, RNA was prepared using TRI zol reagent 
(Invitrogen), and cDNA was prepared as described previously ( 10, 42 ). 
Naive CD4 + T cell cDNA was used for normalization of DR3 expression. 
Expression of DR3 was analyzed by real-time PCR analysis using the SYBR 
green PCR kit (Bio-Rad Laboratories). Expression of GAPDH was used as 
normalization control. Primer sequences are as follows: total DR3, (sense) 
5  -ACACCCTCTTGGCACCTCCAAG-3  and (antisense) 5  -GGCTC-
CAATTTCCGCTTCCC-3  ; total transmembrane DR3 (variants 1 and 3), 
(sense) 5  -GTGACCCTTGAGAACTGCTCGGC-3  and (antisense) 5  -GG A-
ACGCGACTCCTAGAAGCACC-3  ; full-length DR3 (variant 1), (sense) 
5  -GTGACCCTTGAGAACTGCTCGGC-3  and (antisense) 5  -GCCTT-
AGGGCAAACGCTGCTG-3  ; and GAPDH, (sense) 5  -GAGAACTTTG-
GCATTGTGG-3  and (antisense) 5  -ATGCAGGGATGATGTTCTG-3  . 
R. Nurieva and G. Martinez (M.D. Anderson Cancer Center, Houston, TX) 
provided Th17 cDNA and T reg cDNA, respectively. 
 Generation of BMDCs.  Mouse hind limbs were dissected, and tibia and 
fi bula were fl ushed with warm RPMI 1640 medium. Red blood cells were 
lysed, and a single-cell suspension was cultured in RPMI 1640 medium con-
taining GM-CSF for 7 d. Media was replaced every 2 d with fresh RPMI 
1640 medium containing GM-CSF. On day 7, immature BMDCs were 
stimulated with 1  μ g/ml LPS overnight before being used as APCs. Percent-
ages of BMDCs before and after activation were confi rmed by staining for 
CD11c, MHC class II, CD80, and CD86. 
 T cell diff erentiation and inducible T reg cell preparation.  Naive 
OT-II CD4 + T cells were purifi ed from RAG KO/OT-II mice by mag-
netic separation using anti-CD4 magnetic beads, and a cell purity of  > 97% 
was routinely obtained. In some experiments, CD4 + CD62L hi CD25    naive 
T cells or CD4 + CD62L hi CD44 low CD25 +ve n – T reg cells were sorted from 
single-cell suspensions of spleens and lymph nodes by FACS. 0.5  × 10 6 OT-
II cells were cultured at a 20:1 ratio with BMDCs pulsed with 10  μ g/ml 
OT-II peptide, or were cultured with 10  μ g/ml OT-II peptide – pulsed irra-
diated splenocytes at a 1:1 ratio. Additionally, for diff erentiating Th1 cells, 
20 ng/ml IL-12 and 5  μ g/ml anti – IL-4 (clone 11B11) were added to the 
culture. For Th17 diff erentiation, 10 ng/ml mIL-1  , 5 ng/ml hTGF-  , 
20 ng/ml mIL-6, 10  μ g/ml anti – IFN-  (clone XMG1.2), 5  μ g/ml anti – IL-4 
(clone 11B11), and 20 ng/ml mIL-23 were added. For generating Th2 cells, 
20 ng/ml IL-4 and 10  μ g/ml anti – IFN-  were added. For generating T reg 
cells, 5ng/ml hTGF-  (PeproTech), and 10  μ g/ml anti – IFN-  and anti –
 IL-4 were added. Percentages of T reg cells were analyzed by intracellular 
staining using the mouse FoxP3 staining kit according to the manufacturer ’ s 
recommendations (eBioscience). All cytokines used were purchased from 
PeproTech. Human Fc-TL1A, as previously described ( 42 ), or control hu-
man Ig (Sigma-Aldrich) were added as indicated in the fi gures at 1  μ g/ml. 
 DR3 expression is also up-regulated in both n – T reg and 
i – T reg cells, consistent with the observation that TGF-  
signaling primarily up-regulates DR3. In contrast to Th17 
cells, T reg cells also up-regulate a DR3 isoform in which 
there is a deletion of cysteine-rich region IV in the extracel-
lular domain (variant 3), as compared with full-length DR3 
(variant 1). TL1A stimulation did not enhance the prolifera-
tion T reg cells. Our data also demonstrate that diff erentia-
tion of T reg cells is not aff ected by TL1A recombinant 
protein or enhanced in the absence of TL1A signaling in vi-
tro. In addition, we found that the percentages of FoxP3 + 
CD4 + cells in the lymph nodes and spleens of MOG-immu-
nized mice were similar in WT and TL1A KO mice (unpub-
lished data). Further studies are required to understand the 
function of diff erent isoforms of DR3 in T reg cells. 
 The physiological relevance of our fi ndings was addressed 
using TL1A-defi cient mice. TL1A KO mice exhibit a greatly 
decreased percentage of IL-17 + CD4 + T cells, as well as a sig-
nifi cant decrease in the percentages of IFN-  + CD4 + T cells 
and IL-17 + IFN-  + double-producing cells after MOG immu-
nization in vivo. Although TL1A does not regulate Th1 cell 
proliferation or diff erentiation in vitro, TL1A defi ciency ap-
pears to aff ect IFN-  expression in vivo. Future studies are 
needed to investigate how TL1A is regulating these various cy-
tokine producing subsets in vivo. It is possible that TL1A may 
regulate initial IL-2 expression and the extent of T cell prolif-
eration. Alternatively, a defect in IL-17 expression may aff ect 
Th1 diff erentiation, as we recently observed reduced IFN-  
production in IL-17 – defi cient mice (unpublished data). 
 Although Th1 cells and IFN-  have long been implicated 
in infl ammatory autoimmune diseases such as EAE and colla-
gen-induced arthritis, recent studies have shown that Th17 
cells and IL-23 play pivotal roles in promoting infl ammation 
and mediating disease pathogenesis. Our results indicate that 
TL1A-defi cient mice show reduced disease severity and de-
creased accumulation of T cells in the CNS. Furthermore, 
TL1A plays an important role in the EAE disease pathogenesis 
induced by adoptively transferred Th17 cells from MOG-
immunized mice. These data are consistent with the proinfl am-
matory function of Th17 cells in EAE and support a role 
of TL1A in the regulation of Th17 cells in vivo. TL1A may 
function in draining lymph nodes where T cell priming oc-
curs, and/or in CNS tissue where Th17 cells initiate tissue 
infl ammation. Reduced Th17 cells in the spleen and lymph 
nodes in TL1A KO mice after MOG immunization support 
the former. Of note, DCs have been shown recently to pres-
ent antigens and selectively regulate Th17 cells in the CNS 
( 41 ). Reduced cytokine-expressing CD4 + cells in the CNS of 
TL1A KO mice after disease induction supports reduced Th17 
expansion in the tissue, and thereby reduced IL-17 – induced 
chemokine production ( 18 ). 
 In summary, we show in this paper that TL1A expressed 
by mature DCs regulates Th17 diff erentiation, eff ector cell 
expansion, and function in EAE disease through its receptor 
DR3, which is selectively up-regulated in Th17 cells. This 
analysis reveals a novel and unique regulation of Th17 cells. 
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tide (MEVGWYRSPFSRVVHLYRNGK) emulsifi ed in CFA with 400  μ g 
 M. tuberculosis . 10 d later, the spleen and lymph nodes were collected from 
each individual and processed into a single-cell suspension, and stimulated 
with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence of 1  μ g/ml 
Golgi Plug for 5 h, or restimulated overnight with 50  μ g/ml of MOG pep-
tide with Golgo Plug added during the last 5 h. Cells were treated with Fc-
blocking mAbs and surface stained with anti-CD4 – allophycocyanin, 
followed by intracellular staining with PE-conjugated mAb to IL-17 and 
FITC-conjugated mAb to IFN-  , or isotype control mAbs according to the 
manufacturer ’ s instructions (BD Biosciences). Data were acquired using an 
LSRII instrument (Becton Dickinson) and analyzed using FlowJo FACS 
analysis software. Percentages of cytokine-expressing cells within the CD4 + 
population were determined after subtracting the percentages obtained with 
isotype control mAbs. 
 Isolation and analysis of CNS-infi ltrating cells.  At the desired time 
points after EAE induction or adoptive transfer of EAE, animals were killed 
and perfused through the left ventricle with room temperature Ames me-
dium (Sigma-Aldrich) or PBS to remove blood leukocytes. Spinal cords and 
cerebellum or whole brains were collected into ice-cold HBSS with 10% fe-
tal bovine serum. Tissue was disrupted through a 100- μ m strainer, washed 
1 × with HBSS/serum, and resuspended in 5 ml of 37% Percoll (GE Health-
care) in PBS. Gradients were underlayered with 2.5 ml of 70% Percoll in 
PBS and centrifuged at 2,000  g for 20 min. The mononuclear cells were col-
lected from the 37/70 interface, washed with HBSS/serum, and processed 
for FACS staining. For kinetic analysis of CNS-infi ltrating T cells, cells were 
stained with BD Bioscience antibodies for anti-CD45 – PerCP, CD11b-allo-
phycocyanin, and anti-CD4 – PE. For the analysis of intracellular cytokine 
staining, CNS-isolated WT and KO cells (pools of fi ve to six individual mice 
per group) were for the last 5 h with 50 ng/ml of PMA and 500 ng/ml of 
ionomycin in the presence of 1  μ g/ml Golgi Plug. Cells were treated with 
Fc-blocking mAbs and surface stained with anti-CD45 – PerCP and anti-
CD4 – allophycocyanin (BD Biosciences), followed by intracellular cytokine 
staining with PE-conjugated mAbs to IL-17, IFN-  , IL-6, and TNF, a PE-
conjugated mAb to IL-17 and an FITC-conjugated mAb to IFN-  , or iso-
type control mAbs, according to the manufacturer ’ s instructions (BD 
Biosciences). Data were acquired on the LSRII instrument and analyzed 
using the FlowJo FACS analysis software. Absolute numbers of cytokine-
expressing CD4 + cells were calculated. 
 Statistical analysis.  Statistical analysis was performed using Prism soft-
ware (GraphPad), and analysis methods used are indicated in the respective 
fi gure legends. 
 Online supplemental material.  Fig. S1 shows that TL1A-Ig does not in-
duce IL-17 expression by eff ector Th17 cells. Fig. S2 provides an analysis of 
lymphocyte subpopulations and mononuclear cell suspensions in TL1A KO 
and WT spleen, lymph node, thymus, and bone marrow. Fig. S3 describes 
the diff erentiation of naive CD4 + T cells in the presence of WT or TL1A 
KO BMDCs into Th17 and i – T reg cells. Fig. S4 describes the cytokine 
profi le of in vitro restimulation of CD4 + T cells from MOG-primed WT 
and TL1A KO mice. Fig. S5 studies the eff ect of TL1A on the pathogenic-
ity of MOG-specifi c T cells upon in vitro expansion and adoptive trans-
fer. In Fig. S6, DR3 isoform expression was calculated by real-time PCR 
analysis in MOG-specifi c Th17 cells and compared with n – T reg and i – T 
reg cells. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20071364/DC1. 
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 Proliferation and cytokine measurement.  In vitro – diff erentiated cells 
were restimulated on day 5 with a titrating dose of anti-CD3 with or 
without exogenous human Fc-TL1A, as described previously ( 43 ), or 
control human Ig. For anti-CD3 stimulation, 96-well plates were coated 
with the concentration of anti-CD3  (clone 2C11) indicated in the fi g-
ures, and 1.5 – 2  × 10 5 cells were added per well. For restimulation of dif-
ferentiated cells with BMDCs, OVA peptide was titrated and incubated 
with BMDCs, and 1.5  × 10 5 cells T cells were added at a 20:1 ratio with 
DCs. To measure proliferation, including naive and T reg cell experi-
ments, 1  μ Ci [ 3 H]thymidine was added per well during the last 8 h of 
stimulation and harvested, and radioactive incorporation was measured by 
a   -scintillation counter (PerkinElmer). For cytokine measurement, cul-
ture supernatant was harvested at 24 h after stimulation and analyzed by 
ELISA, as previously described ( 18 ). 
 Intracellular cytokine staining of in vitro – diff erentiated Th cells.  Dif-
ferentiated Th cells were harvested on the day indicated in the fi gures, and re-
stimulated with 50 ng PMA and 500 ng/ml ionomycin for 6 h in the presence 
of Golgi Plug (1  μ g/ml Brefeldin A; BD Biosciences). Cells were harvested 
and stained for CD4 (clone RM4-4) and fi xed with 4% paraformaldehyde. 
Cells were then permeabilized with Cytoperm solution (BD Biosciences), and 
stained with anti – mouse IL-17 (clone TC11-18H10.1) and anti – mouse IFN-  . 
At least 50,000 live events were acquired on a FACSVantage system (BD 
Biosciences) and analyzed using FlowJo software (Tree Star, Inc.) 
 EAE induction.  8 – 12-wk-old female C57BL/6 TL1A KO and WT ani-
mals were immunized subcutaneously with 200  μ g MOG 35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK) emulsifi ed in CFA (Chrondex) 
with 200  μ g  Mycobacterium tuberculosis . 50 ng of pertussis toxin (List Biologi-
cal) in PBS was given i.p. at the time of immunization, and 7 – 10 animals 
were used for each experimental group. For adoptive transfer, C57BL/6 
WT mice were immunized subcutaneously with MOG peptide, as de-
scribed, with 400  μ g  M. tuberculosis , and 7 d later the draining lymph nodes 
and spleen cells from MOG-primed animals were restimulated in vitro with 
25  μ g/ml MOG and 20 ng/ml rIL-23 for 7 d. 10 million CD4 + T cells pu-
rifi ed by negative selection using magnetic beads (purity  > 80%) were adop-
tively transferred into WT or TL1A KO recipients by i.p. injection, 
followed by 50 ng of pertussis toxin per mouse i.p. at the time of transfer. 
In some experiments, cells were expanded using 25  μ g/ml MOG, and ei-
ther in the presence or absence of suboptimal 5 ng/ml rIL-23 or in the 
presence or absence of Fc-TL1A for 10 d. CD4 + T cells were then purifi ed 
and adoptively transferred into C57BL/6 recipient mice i.v., followed by 
500 ng/ml of pertussis toxin. Animals were monitored for weight loss and 
development of EAE symptoms. Disease severity was scored as follows: 0, 
no sign of impairment; 1, limp tail; 2, hind limb weakness; 3, hind limb pa-
resis, or paresis of one side of the body and rolling; 4, hind limb paralysis; 
and 5, moribund or dead ( 44 ). 
 Histological evaluation.  Animals were killed, and spinal cords were 
fl ushed out with PBS and fi xed in 4% paraformaldehyde for 72 h. Tissue was 
paraffi  n embedded and cross sectioned using standard protocols. Sections 
were stained for hematoxylin and eosin, Luxol fast blue for myelin, CD3, 
F4/80, Ki-67, Tdt-mediated dUTP-biotin nick-end labeling, and anti-active 
caspase-3 using standard procedures. Tissues were examined microscopically, 
and the CD3 staining was quantifi ed using the MetaMorph image analysis 
software (MDS Analytical Technologies). In brief, a threshold for positive 
brown staining was established, and the total thresholded area was deter-
mined for each spinal cord cross section (at 10 × magnifi cation). The area was 
divided by the mean area of brown staining corresponding to one CD3-pos-
itive cell to calculate the approximate number of CD3-positive cells per spi-
nal cord cross section. Six spinal cord sections were analyzed per animal. 
 Intracellular cytokine expression in the spleen and lymph nodes 
 after MOG immunization.  8 – 12-wk-old female C57BL/6 TL1A KO and 
WT animals were immunized subcutaneously with 200  μ g MOG 35-55 pep-
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